Table 4.
Univariate and multivariate analysis for clinical outcome, microbiological outcome and mortality in patients with SOFA score <7 and ≥7 receiving tigecycline therapy inside the critical care area.
| Variables | Critically ill patients (n = 47) | Univariate model | Adjusted multivariate model* | |||
|---|---|---|---|---|---|---|
| SOFA score < 7 (n = 17) | SOFA ≥7 (n = 30) | P | Odds ratio (95 % confidence interval) | P | ||
| Clinical | ||||||
| Outcome | ||||||
| Success | 14 (31.1%) | 10 (62.5%) | 4 (13.8%) | 0.001 | 12.51 (4.29–36.51) | <0.0001 |
| Failure | 31 (68.9%) | 6 (37.5%) | 25 (86.2%) | |||
| Microbiological | ||||||
| Outcome | ||||||
| Success | 8 (36.4%) | 3 (33.3%) | 5 (38.5%) | 0.81 | 1.29 (0.37–4.54) | 0.69 |
| Failure | 14 (63.6%) | 6 (66.7%) | 8 (61.5%) | |||
| Total mortality | 25 (53.2%) | 2 (11.8%) | 23 (76.7%) | <0.0001 | 5.17 (2.43–11.01) | <0.0001 |
| 7 days post-treatment mortality | 20 (42.6%) | 0 (0.0%) | 20 (66.7%) | <0.0001 | 6.41 (3.04–13.52) | <0.0001 |
| In-hospital mortality | 5 (10.6%) | 2 (11.8%) | 3 (10.0%) | 0.85 | 1.32 (0.63–2.77) | 0.46 |
Potentially confounding variables controlled for in the adjusted model
were: age, cardiovascular disease, FDA-approved indications, off-label indications, community acquired pneumonia, and combination therapy using tigecycline plus aminoglycoside plus colistin.
N.B. Calculation of clinical and microbiological success and failure rates for all categories is done as such:
1-Clinical success rate (%) = Number of patients with clinical success/(Number of patients with clinical success + Number of patients with clinical failure) × 100.
2-Microbiological success rate (%) = Number of patients with microbiological success/(Number of patients with microbiological success + Number of patients with microbiological failure) × 100.